Veteran life sciences technology executive brings more than 25 years of experience scaling commercial organizations and driving innovation across enterprise SaaS and healthcare technology.

BOSTON: Beaconcure, Inc., a leader in trusted AI solutions for clinical development, today announced the appointment of Seth Houston as Chief Executive Officer, effective July 13, 2026. Houston will lead the company through its next phase of growth as life sciences organizations increasingly adopt artificial intelligence to improve the quality, speed, and efficiency of clinical development.

Houston brings more than 25 years of executive leadership experience spanning healthcare technology, enterprise software, and the life sciences industry. Throughout his career, he has built and scaled commercial organizations, developed strategic partnerships, and helped pharmaceutical and medical technology companies leverage innovative software solutions to accelerate business transformation and customer success.

"We are delighted to welcome Seth to Beaconcure," said Anne Whitaker, Interim Chair of the Board. "Seth's proven ability to build high-performing organizations, develop lasting customer relationships, and scale technology companies makes him the right leader for Beaconcure's next chapter. As demand continues to grow for trusted AI solutions in clinical development, we are confident his leadership will help expand our market presence and deliver even greater value to our customers, partners, and employees."

Prior to joining Beaconcure, Houston served as Chief Commercial Officer at MediSpend, where he led the company's global commercial organization, including sales, account management, solution engineering, partner alliances, and marketing. Earlier in his career, he held executive leadership positions at IQVIA, OpenQ, Wolters Kluwer Health, and Proscape Technologies, where he helped life sciences organizations modernize operations through innovative SaaS and data-driven technology solutions.

"I'm honored to join Beaconcure at such an exciting time for both the company and the industry," said Seth Houston, Chief Executive Officer of Beaconcure. "AI is transforming the way life sciences organizations develop and deliver new therapies, and Beaconcure is uniquely positioned to help customers adopt these technologies with confidence. Our platform combines innovation with the quality, transparency, and governance required in regulated environments. I look forward to working alongside our talented team, customers, and partners as we continue to scale the business and help shape the future of clinical development."

Founded in 2016, Beaconcure has become a trusted partner to leading biopharmaceutical companies and CROs by modernizing clinical development through AI-enabled validation, workflow automation, and collaboration. Its Verify platform helps organizations reduce manual effort, improve quality, strengthen compliance, and accelerate the review of clinical analyses while maintaining complete traceability and audit readiness.

About Beaconcure

Beaconcure empowers biopharmaceutical companies and CROs to modernize clinical development through trusted AI solutions for validation, quality, and regulatory workflows. The company's Verify platform enables teams to review, validate, and govern clinical analyses with greater efficiency, transparency, and confidence while maintaining the quality and compliance required for regulated environments.

To learn more about Beaconcure's platform and how it is helping life sciences organizations modernize clinical development, visit www.beaconcure.com.

Fonte: Business Wire